Homology Medicines Inc reports results for the quarter ended in March - Earnings Summary

Q32 Bio

16/05/2022 23:27

* Homology Medicines Inc  FIXX.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in March. The
mean expectation of nine analysts for the quarter was for a loss
of 35 cents per share.
    * Revenue fell 97.3% to $802.00 thousand from a year ago; 
analysts expected $20.69 million. 
    * Homology Medicines Inc's reported EPS for the quarter was
$1.59​.
    * The mean earnings estimate of analysts had risen by
about 39.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Homology Medicines Inc shares had fallen by 53.9% this
quarter and lost 61.5% so far this year.
    * The company reported quarterly net income of $92.11
million.
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $9.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 10:27 p.m.  ​All
figures in US dollars unless otherwise stated